Abstract
Malignant peritoneal mesothelioma (MPeM) is an aggressive cancer of the peritoneal lining of the abdominal cavity. Though early stage MPeM has better outcomes with multimodal treatment, advanced, non-resectable disease has a poor prognosis. No prognostic indicators are available to inform clinical decision-making. We hypothesize inflammatory biomarkers may provide a means of survival assessment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
